Tacrolimus has been shown to be more effective than cyclosporine for prevention of acute graft-versus-host disease (GVHD). A number of transplant centers have therefore adopted tacrolimus as standard prophylaxis, but with additional experience, current management of tacrolimus differs from that in the clinical studies. Therefore, a consensus conference was convened to assess the current practices. For prevention of GVHD, conference participants recommended administering tacrolimus at 0.03 mg/kg/day (by lean body weight) i.v. by continuous infusion from day ؊1 or ؊2 pretransplant, with day ؊2 used especially for pediatric patients. Therapeutic drug monitoring was considered essential in the management of patients on tacrolimus. The consensus target range for the whole blood concentration was 10-20 ng/ml. Doses were modified for blood levels outside the target range or for nephrotoxicity, and tacrolimus was discontinued for intolerable tremor, hemolytic uremic syndrome, leukoencephalopathy or other serious toxicity. Tacrolimus was employed most frequently in combination with minimethotrexate (5 mg/m 2 i.v. days 1, 3, 6 and 11). Tapering was individualized according to center practice. No patient category was excluded from use of tacrolimus based on age, extent of disease, patient-donor histocompatibility or stem cell source. Tacrolimus was also used successfully for treatment of chronic GVHD. The responsiveness of steroidrefractory acute GVHD was marginal, so it was deemed more prudent to use tacrolimus for prophylaxis instead. Keywords: tacrolimus; graft-versus-host disease; allogeneic marrow transplantation; therapeutic drug monitoring Tacrolimus was first evaluated in marrow transplant recipients in 1990.
ment of refractory acute or chronic GVHD were readily apparent. Subsequently, three randomized studies conducted in 17 North American centers and 21 Japanese centers compared tacrolimus and cyclosporine in combination with standard-dose methotrexate for prevention of GVHD after HLA-identical sibling or unrelated donor marrow transplantation. [2] [3] [4] The studies revealed that tacrolimus was superior to cyclosporine for prevention of acute GVHD in these settings, although long-term leukemia-free survival was not affected. For many of the participating centers, the randomized studies were their first experience with tacrolimus.
Several centers have since adopted tacrolimus as the standard agent for GVHD prophylaxis, and more than 500 patients have been treated outside the sponsored trials. [5] [6] [7] [8] [9] [10] [11] Investigators from these centers were convened at a consensus conference in Key West in November 1998 to review the current practices by those experienced with tacrolimus for prevention of GVHD, determine if there is a consensus in the use of tacrolimus, and identify where additional information is needed.
What are the advantages and disadvantages of the use of tacrolimus for prevention of GVHD?
The major advantage identified by all participants was that tacrolimus was associated with a significantly lower risk of acute GVHD after HLA-identical and unrelated donor marrow transplantation. The reduction in GVHD was realized without an increase in relapse, graft failure, infection or lymphoproliferative disease over that seen in the cyclosporine-treated patients. A decrease in morbidity and in cost were cited as the clinical benefits resulting from the reduction in acute GVHD. The issue of cost was discussed extensively. Two institutions indicated that tacrolimus was used over cyclosporine, because its use reduced the actual cost of the immunosuppressive regimen. An indirect saving was also realized by avoiding the increased cost of treating acute GVHD, which was estimated to be approximately $50 000 per case. 12, 13 Improved patient tolerance of the drug with less hirsutism, gingival hyperplasia and facial dysmorphism were also cited as clinical benefits for the use of tacrolimus.
Participants discussed the experience with tacrolimus for marrow, blood stem cell and cord blood transplantation using haploidentical, mismatched related, matched or mismatched unrelated, and haploidentical donors. There were no concerns raised about use of tacrolimus in any of the subgroups. When assessing the survival disadvantage in the advanced disease patients in the randomized sibling study, 3 the participants unanimously felt that this resulted from an imbalance in randomization of patients with poor prognosis. The case-control study showing no difference in survival for cyclosporine-treated disease-matched controls compared to the tacrolimus arm was cited to support this opinion.
14 In fact, advanced leukemia was the indication for transplantation where tacrolimus was used most frequently by the participants.
A question was raised regarding the inconsistency between clear reduction in acute GVHD and absence of a survival advantage in the standard-risk leukemia patients treated with tacrolimus in the randomized studies. [2] [3] [4] It was pointed out that it is a rare supportive care study which demonstrates a survival advantage in addition to the primary activity, and despite this, over the past 10 years there has clearly been an increase in survival for transplant recipients. It was concluded that the incremental improvements in outcome afforded by single changes in supportive care could not be detected in the individual studies because of the relatively small numbers of patients, but when multiple changes in supportive care are considered in aggregate, the improvement in outcome is obvious.
The only disadvantage cited for use of tacrolimus was that the intravenous formulation was given by continuous infusion. This was the preferred method of administration, because of the high rates of neurologic and renal toxicities seen when the drug was administered by rapid or short infusions twice daily. However, it was pointed out that the dose of drug given by short infusion in those early solid organ transplant patients was much higher than that used for marrow transplantation, and there is no published experience with shorter infusions using the current lower dose.
What is the tacrolimus dose-schedule for GVHD prophylaxis?
The initial dose of tacrolimus is 0.03 mg/kg/day i.v. based on lean body weight. The use of lean rather than actual body weight was considered by some a departure from their usual method for dosing cyclosporine. The participants initiated administration of tacrolimus on the morning of day Ϫ1 or the evening of day Ϫ2 prior to transplantation. Recent data were cited regarding the fact that pediatric patients have a higher clearance of tacrolimus. 15, 16 Despite this, those treating pediatric patients did not utilize a higher initial dose; they recommended that the drug be started on day Ϫ2 in children to ensure that steady state had been achieved by the time of transplantation.
All centers continued intravenous administration through engraftment, with conversion to oral in a 1:4 i.v.:p.o. ratio, and oral drug was given in two divided doses daily. It was pointed out, however, that a proportion of patients have a higher absorption of tacrolimus, so patients should be monitored closely when converting to oral drug to ensure appropriate dosing.
The duration of administration of tacrolimus varied between centers and depended on the indication for transplantation. The recommendation made was to taper tacrolimus in a fashion similar to how one would using cyclosporine.
How are patients monitored during treatment with tacrolimus, and how are doses modified?
All participants indicated that whole blood levels of tacrolimus were measured regularly, and the results were used for dose modifications. This was cited as another departure from the standard management of cyclosporine, wherein many of the investigators modified doses of cyclosporine only if toxicity was seen. Support cited for the practice of close therapeutic monitoring when using tacrolimus included two analyses which showed a sharp increase in nephrotoxicity with whole blood levels exceeding 20 ng/ml. 17, 18 In general, whole blood levels were measured beginning 24 to 48 h after initiation of the i.v. infusion. Measurements were made at least three times per week in the peritransplant period, and once or twice per week in stable outpatients. There was no indication for continued therapeutic monitoring once tapering had begun if the patient remained stable.
More frequent measurement of whole blood levels was indicated in patients who became acutely ill, especially when developing liver dysfunction, or after starting treatment with drugs known to have a pharmacologic interaction with tacrolimus. Pre-emptive dose modification when starting such drugs, or when starting nephrotoxic agents such as amphotericin, was not utilized by any of the study participants. For these situations, it was considered more prudent to monitor drug levels more frequently rather than to lower the dose and risk development of GVHD.
Frequent monitoring of creatinine routinely accompanied the use of tacrolimus, and dose modifications were recommended on the basis of both renal insufficiency (Table  1) and whole blood drug levels ( Table 2 ). The target therapeutic range cited was 10-20 ng/ml. The upper limit of 20 ng/ml comes from the analysis correlating toxicity with higher blood levels. 17, 18 The lower limit of 10 ng/ml was due to the fact that there is less published experience using lower target levels. A number of centers have used an upper level of 15 ng/ml, which allowed for an interval of 5 ng/ml before getting into the range of increased risk of nephrotoxicity. Some centers have also allowed the blood levels to remain in the 5 to 10 ng/ml range if the patient is clinically stable. A small amount of experience with whole blood tacrolimus levels below 5 ng/ml suggested that the risk of Table 1 Tacrolimus dose modification for renal insufficiency
Serum creatinine Tacrolimus dose
1.0-1.5 ϫ baseline 75-100% of current dose 1.6-1.9 ϫ baseline 25-50% of current dose Ͼ1.9 ϫ baseline Hold and resume at 50% of current dose if renal dysfunction is stable Tacrolimus clearance may be excessively prolonged for patients with liver dysfunction or while on medication that inhibits hepatic P450 function. In these patients, hold tacrolimus and follow levels daily to determine when to restart administration.
GVHD was increased, and levels below 5 ng/ml were to be avoided.
What were the indications to discontinue use of tacrolimus?
The experience of the participants indicated that the toxicity profile of tacrolimus was similar to that of cyclosporine, except that fewer patients on tacrolimus had hypertension. 3, 4, 19 Intolerable side-effects were identified as the most common reason to discontinue tacrolimus. These included severe tremor, hemolytic uremic syndrome (HUS) and leukoencephalopathy. It was felt that tremor was not doserelated but idiosyncratic; however, no data were available regarding whether patients with tremors on tacrolimus were tolerant of cyclosporine. Not all participants uniformly discontinued use of tacrolimus for HUS or leukoencephalopathy. In some cases, the drug was stopped only temporarily, or the dose was reduced and subsequently continued without recurrence of HUS or leukoencephalopathy. However, most participants preferred to utilize an alternative immunosuppressive drug in these circumstances. A number of participants have also used tacrolimus for patients who had developed HUS or leukoencephalopathy while receiving cyclosporine without either of these toxicities recurring. However, the numbers of patients developing HUS or leukoencephalopathy were too small to allow firm conclusions regarding management of immunosuppressive therapy.
Should tacrolimus be used alone or in combination with other immunosuppressive drugs for GVHD prophylaxis?
Monotherapy has been used successfully for GVHD prophylaxis, 20 and selected centers have continued to use monotherapy when the risk of GVHD is not considered to be high. The advantages of combination therapy over monotherapy were first reported in a preclinical study, 21 and a similar conclusion was drawn in a recent retrospective analysis comparing tacrolimus to tacrolimus and methotrexate for HLA-identical blood stem cell transplantation. 22 The investigators listed methotrexate, 23 methylprednisolone, daclizumab and other monoclonal anti-T cell antibodies, mycophenolate mofetil, thalidomide and antithymocyte globulin as other immunosuppressives used in combination with tacrolimus without clinically apparent adverse interactions.
Although the North American studies utilized standard dose methotrexate, most participants currently employ the minimethotrexate regimen (methotrexate 5 mg/m 2 i.v. days 1, 3, 6 and 11). The rationale for the lower dose of methotrexate was a safety issue. Most investigators found that standard-dose methotrexate could not be tolerated by patients receiving current preparative regimens because of extreme mucositis. Moreover, in a phase II multicenter trial of tacrolimus for GVHD prophylaxis after unrelated donor transplantation, there was no difference in risk of GVHD between the groups treated with standard methotrexate or with minimethotrexate.
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How should tacrolimus be used for treatment of acute GVHD?
For patients developing acute GVHD while on tacrolimus, all participants recommended measuring the whole blood tacrolimus concentration to ensure that it was in the therapeutic range. All agreed that if the blood level was within the range, the dose should not be increased further, since there was no evidence to suggest that increasing blood levels above the target range was beneficial, but there was substantial evidence that it would increase toxicity. 17, 18 Thus, for patients developing acute GVHD while on tacrolimus with a therapeutic blood level, initiation of treatment with high-dose corticosteroids was indicated. For patients developing visceral GVHD while on oral tacrolimus, it was recommended that intravenous dosing be utilized, since it is not known whether the peak level or the AUC contributed to the activity of the drug.
For patients developing acute GVHD while on cyclosporine, there was some experience discussed using tacrolimus as salvage therapy. The response rate for patients with steroid-refractory acute GVHD treated with tacrolimus was generally less than 20%, and survival was poor. The strategy of using tacrolimus only for treatment of acute GVHD was reviewed; however, because of the very low response rate, this strategy was considered unacceptable.
How should tacrolimus be used for treatment of chronic GVHD?
Participants indicated that they had used tacrolimus successfully for treatment of chronic GVHD developing off immunosuppressive therapy and as salvage therapy for patients who were cyclosporine failures. In these cases, tacrolimus was administered the same way as for prophylaxis, although the drug could be started orally at 0.06 mg/kg twice daily. The therapeutic target range and monitoring of drug levels and creatinine were also the same as recommended for prophylaxis. When used for front-line ther-apy of chronic GVHD, most participants used monotherapy or combination therapy with corticosteroids as they would previously have used with cyclosporine, and the duration of therapy was also the same as with cyclosporine.
In summary, the study participants uniformly favored use of tacrolimus over cyclosporine as GVHD prophylaxis because of the reduction in morbidity associated with the lower incidence of acute GVHD. Experience demonstrated tacrolimus was an active immunosuppressive agent for alternative donor transplantation as well as with transplantation of hematopoietic stem cells other than marrow, and the lower dose-schedule of methotrexate was used by most of the participants in conjunction with tacrolimus. The consensus dose-schedule of tacrolimus was 0.03 mg/kg/day by continuous infusion, and therapeutic monitoring was used to ensure that the tacrolimus whole blood concentration remained in the range of 10-20 ng/ml. Doses were also modified for nephrotoxicity and other serious adverse events, but more information was needed regarding use of tacrolimus in patients with hemolytic-uremic syndrome and leukoencephalopathy after transplantation.
